levomilnacipran
Selected indexed studies
- Levomilnacipran. (, 2006) [PMID:29999699]
- Levomilnacipran: More of the Same? (Prim Care Companion CNS Disord, 2019) [PMID:31509357]
- Levomilnacipran extended release: first global approval. (Drugs, 2013) [PMID:24000002]
_Worker-drafted node — pending editorial review._
Connections
levomilnacipran is a side effect of
Sources
- Levomilnacipran. (2006) pubmed
- Levomilnacipran: More of the Same? (2019) pubmed
- Levomilnacipran extended release: first global approval. (2013) pubmed
- Levomilnacipran: a newly approved drug for treatment of major depressive disorder. (2014) pubmed
- Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder. (2014) pubmed
- Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. (2014) pubmed
- LEVOMILNACIPRAN--A SUCCESSOR OF MILNACIPRAN WITH A HIGHER NORADRENERGIC SELECTIVITY. (2016) pubmed
- Levomilnacipran ameliorates lipopolysaccharide-induced depression-like behaviors and suppressed the TLR4/Ras signaling pathway. (2023) pubmed
- Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? (2013) pubmed
- Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. (2014) pubmed